Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alexion Pharmaceuticals, Inc.
Alexion's Soliris® Receives 2009 Prix Galien France for Most Innovative Drug for Rare Disease
July 3rd, 2009
Alexion Pharma France and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today received the 2009 Prix Galien France for Soliris® (eculizumab) in the category of medicines for rare diseases. The award recognizes the scientific innovation represented by the complement-inhibition technology of Soliris, and the impact the drug is having on the lives of patients with paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare, debilitating and life-threatening blood disorder. Soliris is a first-in-class terminal complement inhibitor that selectively blocks the formation of terminal complement, a component of the normal immune system. Patients with PNH lack naturally occurring...
Source: Health Business Week (2009-07-03)
|
